PUMA BIOTECHNOLOGY, INC. (PBYI) SEC Filings & Earnings Calls

R&D expense increase may pressure near-term margins; clinical trial costs rising.

“R&D expenses increased $9.4M year-over-year for first six months, primarily due to alisertib study activity.”

Operating cash flow declined significantly YoY; debt repayment may have impacted liquidity.

“Net cash provided by operating activities for Q2 2026 was $1.6M vs $14.1M in Q2 2025.” · word for word

Royalty rate reduction in China

“Under our sub-license agreement covering China, the royalty rate payable to us is subject to reduction when the market share of generic versions of NERLYNX in China reaches a specified threshold. We are unable to predict with certainty when this threshold will be reached. However, we believe it is possible that the threshold could be reached, triggering the ” · word for word

Pharmaceutical tariff impact

“On April 2, 2026, the U.S. government issued a proclamation under Section 232 of the Trade Expansion Act of 1962, imposing a 100% ad valorem duty, subject to specified exclusions, on the import of patented pharmaceutical products listed in the FDA’s Orange Book or Purple Book, as well as their associated APIs.” · word for word

Alisertib development funding needs

“Going forward, we anticipate significant expenses as we continue to develop alisertib in 2026. Accordingly, our success depends not only on the safety and efficacy of our drug candidates, but also on our ability to finance product development.” · word for word

Single product dependency on NERLYNX; revenue decline in Q1 despite demand increase.

“Product revenue entirely from NERLYNX; Q1 product revenue down 2.6% YoY.”

Increased R&D spending on alisertib trials may pressure near-term profitability.

“R&D expenses $19.8M vs $13.8M, up $6.0M primarily due to alisertib study activity.”

Alisertib development funding needs

“Going forward, we anticipate significant expenses as we continue to develop alisertib in 2026. Accordingly, our success depends not only on the safety and efficacy of our drug candidates, but also on our ability to finance product development.” · word for word

Pharmaceutical tariff impact

“On April 2, 2026, the U.S. government issued a proclamation under Section 232 of the Trade Expansion Act of 1962, imposing new tariffs on imported patented pharmaceutical products and APIs. Any potential impact of the proclamation on the Company is uncertain and under review.” · word for word

Single-product dependency on NERLYNX

“Product revenue for the year ended December 31, 2025 increased to approximately $204.1 million, compared to approximately $195.2 million for the year ended December 31, 2024, due primarily to a 5.5% increase in bottles of NERLYNX sold” · word for word

Royalty revenue decline from China sub-licensees

“Royalty revenue for the year-ended December 31, 2025, decreased to approximately $24.3 million, compared to approximately $35.3 million for the year-ended December 31, 2024, primarily related to an anticipated decrease in sales by our sub-licensees into China” · word for word

Pipeline dependency on alisertib clinical trials; no near-term revenue from alisertib

“R&D expenses increased to $62.1M in FY2025 from $54.9M in FY2024 due to alisertib study activity. Alisertib is in Phase II trials with no approved product.”

Valuation allowance adjustments can materially impact net income

“Q4 2025 included a net change in valuation allowance that unfavorably impacted net income by $3.2M. Q4 2024 had a partial release that favorably impacted by $7.1M.”

Single Product Dependency

“We are currently a single product company with limited commercial sales experience.” · word for word

Customer Concentration

“In 2025, five customers individually comprised approximately 27.3%, 17.0%, 16.4%, 13.1% and 10.6%, respectively, of our total product revenue.” · word for word

IRA Drug Pricing Pressure

“NERLYNX is reimbursed under Medicare Part D, and we have incurred IRA inflation rebates. We anticipate that these increased discounts will impact NERLYNX revenues over time.” · word for word

Debt Covenant Risk

“The terms of our Note Purchase Agreement place restrictions on our ability to operate our business and on our financial flexibility, and we may be unable to achieve the revenue necessary for us to incur additional borrowings under the Note Purchase Agreement or to satisfy the minimum revenue and cash balance covenants.” · word for word

Alisertib Development Failure

“We are in the early stages of development of alisertib, and we cannot be certain that we will be successful if we seek regulatory approvals for our drug candidates.” · word for word

Royalty revenue decline due to China sales reduction; concentration risk on NERLYNX single product.

“Royalty revenue dropped from $24.4M to $2.6M YoY; product revenue net down 7.5% despite U.S. volume growth.”

Increasing Gross to Net adjustment (23-23.5% vs prior 21.5-22%) pressures net revenue.

“Gross to Net Adjustment guided to 23%–23.5% for FY2025 (updated) vs prior 21.5%–22%.”

R&D spend increasing as alisertib trials advance; no near-term revenue from pipeline.

“R&D expenses increased $5.4M YoY in first nine months due to increased alisertib study activity.”

Dependence on China sales for royalty revenue

“The decrease was primarily due to timing of sales made into China by our sub-licensee.” · word for word

Debt covenant compliance risk

“We are also required to maintain minimum cash balances and achieve certain minimum product revenue targets, measured as of the last day of each fiscal quarter on a trailing year-to-date basis.” · word for word

Concentration of revenue in NERLYNX

“Product revenue, net consists of revenue from sales of NERLYNX.” · word for word